Status:

UNKNOWN

Identification by Transcriptomic Approach of New Prognostic and Predictive Markers in a Cohort of Atypical Meningiomas

Lead Sponsor:

Central Hospital, Nancy, France

Collaborating Sponsors:

Institut National de la Santé Et de la Recherche Médicale, France

Conditions:

Meningioma Atypical

Eligibility:

All Genders

18+ years

Brief Summary

Determine by a transcriptomic approach new prognostic and predictive markers in atypical meningiomas (WHO grade II). Retrospective observational study, on a cohort of 85 atypical meningiomas. Transcr...

Eligibility Criteria

Inclusion

  • Primary operated patients for an atypical meningioma (WHO grade II) in the Neurosurgery department of the University Hospital of Nancy.
  • At least one postoperative follow-up visit.
  • Adult patients (\>18 yo) at the time of the intervention.
  • Surgical excision.

Exclusion

  • History of meningioma in the same location.
  • Neo-adjuvant treatment.
  • Absence of non-objection form.

Key Trial Info

Start Date :

February 25 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

October 31 2023

Estimated Enrollment :

85 Patients enrolled

Trial Details

Trial ID

NCT05259332

Start Date

February 25 2022

End Date

October 31 2023

Last Update

February 28 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Guillaume GAUCHOTTE

Vandœuvre-lès-Nancy, Lorraine, France, 54511